Bradykinin release of TNF-α plays a key role in the development of inflammatory hyperalgesia
Authors:
- 1 June 1993
- journal article
- neurogenic pain-and-inflammation
- Published by Springer Nature in Inflammation Research
- Vol. 38 (S2) , C7-C9
Abstract
Using specific antisera for IL-1β and IL-8, as well as cyclooxygenase inhibitors and propranolol, we have demonstrated that these cytokines are responsible for the prostaglandin and sympathetic components of carrageenin-induced hyperalgesia in the rat paw test. The release of IL-1β and IL-8 is preceded by the liberation of TNF-α. We have also tested in a nociceptive model the effects of bradykinin and a specific bradykinin antagonist, HOE 140, on the hyperalgesia induced by carrageenin and lipopolysaccharide (LPS). Bradykinin-induced hyperalgesia was abolished by HOE 140 and by treatment of the paws with anti-TNF-α antisera. HOE 140 significantly inhibited the hyperalgesia induced by carrageenin and LPS. It is suggested that in these two models bradykinin is associated with the release of hyperalgesic cytokines.Keywords
This publication has 7 references indexed in Scilit:
- The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesiaBritish Journal of Pharmacology, 1992
- Interleukin‐8 as a mediator of sympathetic painBritish Journal of Pharmacology, 1991
- Bradykinin stimulates tumor necrosis factor and interleukin‐1 release from macrophagesFEBS Letters, 1989
- Interleukin-1β as a potent hyperalgesic agent antagonized by a tripeptide analogueNature, 1988
- A peripheral sympathetic component in inflammatory hyperalgesiaEuropean Journal of Pharmacology, 1987
- Interleukin-1 and the Pathogenesis of the Acute-Phase ResponseNew England Journal of Medicine, 1984
- Central and peripheral antialgesic action of aspirin-like drugsEuropean Journal of Pharmacology, 1978